Literature DB >> 15673762

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.

Varsha Moudgal1, Tania Little, Dina Boikov, Jose A Vazquez.   

Abstract

Echinocandins are approved for the treatment of candidal infections. In vitro they have been shown to be less potent against strains of Candida parapsilosis than against other Candida spp. This is the first case report describing the development of a secondary multidrug (echinocandin-azole)-resistant Candida strain during therapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15673762      PMCID： PMC547225          DOI： 10.1128/AAC.49.2.767-769.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Echinocandins: a new class of antifungal.

Authors:  David W Denning
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

2.  Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Authors:  J Onishi; M Meinz; J Thompson; J Curotto; S Dreikorn; M Rosenbach; C Douglas; G Abruzzo; A Flattery; L Kong; A Cabello; F Vicente; F Pelaez; M T Diez; I Martin; G Bills; R Giacobbe; A Dombrowski; R Schwartz; S Morris; G Harris; A Tsipouras; K Wilson; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

Authors:  M A Pfaller; D J Diekema; R N Jones; S A Messer; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.

Authors:  Stefano P Bachmann; Thomas F Patterson; José L López-Ribot
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Caspofungin.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  An outbreak of Candida parapsilosis prosthetic valve endocarditis.

Authors:  D J Diekema; S A Messer; R J Hollis; R P Wenzel; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1997-11       Impact factor: 2.803

Review 8.  Caspofungin: an echinocandin antifungal agent.

Authors:  Elizabeth A Stone; Horatio B Fung; Harold L Kirschenbaum
Journal:  Clin Ther       Date:  2002-03       Impact factor: 3.393

Review 9.  Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.

Authors:  A H Groll; T J Walsh
Journal:  Expert Opin Investig Drugs       Date:  2001-08       Impact factor: 6.206

10.  Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.

Authors:  Tamara Koss; Bita Bagheri; Cosmina Zeana; Mario F Romagnoli; Marc E Grossman
Journal:  J Am Acad Dermatol       Date:  2002-06       Impact factor: 11.527
View more
  66 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates.

Authors:  Ronald N Jones; Mariana Castanheira; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye.

Authors:  Deb K Mojumder; Francis A Concepcion; Shil K Patel; Andrew J Barkmeier; Petros E Carvounis; John H Wilson; Eric R Holz; Theodore G Wensel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-26       Impact factor: 4.799

Review 4.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

5.  Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Authors:  Jeffrey M Rybak; C Michael Dickens; Josie E Parker; Kelly E Caudle; Kayihura Manigaba; Sarah G Whaley; Andrew T Nishimoto; Arturo Luna-Tapia; Sujoy Roy; Qing Zhang; Katherine S Barker; Glen E Palmer; Thomas R Sutter; Ramin Homayouni; Nathan P Wiederhold; Steven L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Authors:  Morgan Hakki; Janet F Staab; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 7.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 8.  Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting.

Authors:  Brian D W Chow; Jennifer R Linden; Joseph M Bliss
Journal:  Expert Rev Anti Infect Ther       Date:  2012-08       Impact factor: 5.091

9.  Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.

Authors:  Shawn R Lockhart; Shawn A Messer; Michael A Pfaller; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2008-06-18       Impact factor: 5.948

Review 10.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.